| Breast cancer during pregnancy: maternal and fetal outcomes. | |
| | |
MedLine Citation:
|
PMID: 20164696 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Breast cancer is the most common malignancy occurring during pregnancy. Because more women delay childbearing, the diagnosis of cancer during pregnancy will likely increase. Case reports exist in the literature regarding the treatment of pregnant women with breast cancer, but few are prospective and few provide long-term follow-up on the neonate exposed to chemotherapy. In this report, 130 women diagnosed with breast cancer were reported to our voluntary national registry and followed up prospectively. PATIENT AND METHODS: The Cancer and Pregnancy Registry is a voluntary registry that monitors the clinical course, treatment, and disease outcome of women diagnosed with cancer during pregnancy and the perinatal and neonatal outcomes of their children. RESULTS: Of the 130 diagnosed, 120 were diagnosed with a primary tumor, 8 with a recurrence, and 2 with a new primary cancer. Mean maternal age at diagnosis was 34.8 +/- 4.2 years. Mean gestational age at diagnosis was 13.2 +/- 8.1 weeks. Gestational age was 12.8 +/- 7.8 weeks for patients with primary disease and 16.25 +/- 11 weeks for those with recurrent cancer. One hundred thirteen women were followed up for mean of 3.14 +/- 2.5 years. Of those followed up, 103 were diagnosed with primary breast cancer during pregnancy, 8 with a recurrence, and 2 with a new primary. Recurrence was reported in 30 patients at an average of 16.2 +/- 10.8 months from delivery to recurrence. Twenty-one patients are deceased with an average of 24.71 +/- 15.32 months from delivery to death. Only 42% were diagnosed with an estrogen-positive tumor and 35% of cases had a progesterone receptor-positive tumor. Human epidermal growth factor receptor 2 was positive in 25% of patients. Chemotherapy was given during pregnancy in 104 cases; the first treatment was given at a mean gestational age of 20.4 +/- 5.4 weeks. The malformation rate of exposed neonates was 3 not greater than the general population. Survival by stage for a primary diagnosis in pregnancy is as follows: stage I, 100%; stage II, 86%; stage III, 86%; and stage IV, 0%. DISCUSSION: Pregnant women diagnosed with breast cancer can receive treatment comparable with nonpregnant women leading to a similar survival when matched for stage at diagnosis. The majority of children who were exposed to chemotherapy in utero did not demonstrate significant complications. We report the single largest cohort of women diagnosed with breast cancer during pregnancy. |
| | |
Authors:
|
Elyce Cardonick; Rebecca Dougherty; Generosa Grana; Dzhamlaa Gilmandyar; Sadia Ghaffar; Aniqa Usmani |
Related Documents
:
|
15198046 - Oropharyngeal carcinoma during pregnancy: clinical and psycho-oncological aspects. 18795086 - Successful childbirth in a patient with chronic myelogenous leukemia treated with imati... 19752526 - Pregnancy outcome in maternal crigler-najjar syndrome type ii: a case report and system... 10071276 - Management of breast cancer during pregnancy using a standardized protocol. 7869066 - Maternal build and pregnancy outcome. 1340656 - Endocrine abortion in assisted reproduction technologies (art). |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer journal (Sudbury, Mass.) Volume: 16 ISSN: 1540-336X ISO Abbreviation: Cancer J Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-02-18 Completed Date: 2010-05-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100931981 Medline TA: Cancer J Country: United States |
Other Details:
|
Languages: eng Pagination: 76-82 Citation Subset: IM |
Affiliation:
|
Departments of Obstetrics and Gynecology, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, Camden, NJ, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / therapeutic use* Breast Neoplasms / diagnosis*, drug therapy, surgery Combined Modality Therapy Female Follow-Up Studies Gestational Age Humans Infant, Newborn Middle Aged Neoplasm Recurrence, Local / diagnosis*, drug therapy, surgery Neoplasm Staging Pregnancy Pregnancy Complications, Neoplastic / diagnosis*, drug therapy, surgery Pregnancy Outcome Prospective Studies Registries Risk Factors Survival Rate Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
| Comments/Corrections | |
Comment In:
|
Cancer J. 2010 Jan-Feb;16(1):68-9
[PMID:
20164694
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patien...
Next Document: Hormone replacement therapy and messenger RNA expression of estrogen receptor coregulators after exe...